X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
PT217 is a first-in-class native IgG-like bispecific antibody (bsAb) targeting DLL3 and CD4. It is being evaluated for the treatment of patients with extensive-stage small cell lung cancer.
Lead Product(s): PT217
Therapeutic Area: Oncology Product Name: PT217
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 08, 2024
Details:
PT886 is a first-in-class native IgG-like bispecific antibody (bsAb) targeting claudin 18.2 and CD47, is being developed for the treatment of patients with gastric, gastroesophageal junction and pancreatic adenocarcinomas.
Lead Product(s): PT-886,Pembrolizumab,Pemetrexed
Therapeutic Area: Oncology Product Name: PT-886
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 20, 2024
Details:
The collaboration aims to study PT886, a first-in-class bispecific antibody targeting claudin 18.2 and CD47, in combination with Merck's anti-PD-1 therapy, Keytruda (pembrolizumab), in patients with claudin 18.2 positive gastric or gastroesophageal junction adenocarcinomas.
Lead Product(s): PT886,Pembrolizumab
Therapeutic Area: Oncology Product Name: PT886
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Merck & Co
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration October 16, 2023
Details:
PT217 is a common light chain bispecific antibody discovered through Phanes' research engine and was granted orphan drug designation (ODD) for the treatment of small cell lung cancer by the FDA last year.
Lead Product(s): PT217
Therapeutic Area: Oncology Product Name: PT217
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 07, 2023
Details:
PT886 directly kills tumor cells via both the ADCP activity of macrophages and ADCC activity of NK cells, and by targeting both claudin 18.2 and CD47 overexpressed on the surface of tumor cells, it broadens the tumor killing spectrum.
Lead Product(s): PT886
Therapeutic Area: Oncology Product Name: PT886
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 20, 2023
Details:
The collaboration will leverage Phanes’ proprietary technology platforms, PACbody and SPECpair, in the evaluation of cell therapies in oncology. The company has its proprietary technology platforms to develop novel biologics that address high unmet medical needs in cancer.
Lead Product(s): Bispecific Antibody
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: DiscoveryProduct Type: Large molecule
Partner/Sponsor/Collaborator: Xyphos Biosciences
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration March 06, 2023
Details:
Phanes therapeutics’ first-in-class bispecific antibody, PT886 is an anti-claudin 18.2/anti-CD47 bispecific antibody being developed for gastric and pancreatic cancers.
Lead Product(s): PT886
Therapeutic Area: Oncology Product Name: PT886
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 17, 2023
Details:
PT199 is an anti-CD73 monoclonal antibody with a differentiated mechanism of action and is designed to counter the adenosine-mediated immunosuppressive tumor microenvironment (TME).
Lead Product(s): PT199,Tislelizumab
Therapeutic Area: Oncology Product Name: PT199
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: BeiGene
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement December 08, 2022
Details:
PT217 is a first-in-class bispecific antibody targeting Delta-like ligand 3 (DLL3) and cluster of differentiation 47 (CD47) being developed for patients with SCLC and other neuroendocrine cancers.
Lead Product(s): PT217
Therapeutic Area: Oncology Product Name: PT217
Highest Development Status: IND EnablingProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 14, 2022
Details:
PT199 is an anti-CD73 mAb with a differentiated mechanism of action and is designed to counter the adenosine-mediated immunosuppressive tumor microenvironment (TME).
Lead Product(s): PT199,Undisclosed
Therapeutic Area: Oncology Product Name: PT199
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 23, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
